Firefly Neuroscience (AIFF) Gains from Investment Securities (2022)
Firefly Neuroscience (AIFF) posted Gains from Investment Securities of -$942609.0 for Q2 2022, down 7575.68% on a QoQ basis from $12609.0 in Q1 2022.
Powered by 
Analysis
Firefly Neuroscience (AIFF) Gains from Investment Securities (2022) Analysis & Trends
Firefly Neuroscience has reported Gains from Investment Securities for 1 years, with the latest figure at -$942609.0 in Q2 2022.
- On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to -$942609.0 in Q2 2022; TTM through Dec 2022 was -$930000.0, a N/A change from a year earlier, with the FY2022 full-year figure at -$930000.0, changed N/A from the prior year.
- Gains from Investment Securities was -$942609.0 for Q2 2022 at Firefly Neuroscience, down from $12609.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $12609.0 in Q1 2022, with the low at -$942609.0 in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | GE HealthCare Technologies | 31.10 Bn | 29.22 Bn | 2.18 Bn |
| 2 | Lantheus Holdings | 6.59 Bn | 6.00 Bn | 241.86 Mn |
| 3 | Heartflow | 4.24 Bn | 3.87 Bn | 53.19 Mn |
| 4 | Neogen | 2.58 Bn | 2.39 Bn | 107.80 Mn |
| 5 | Butterfly Network | 1.75 Bn | 1.62 Bn | 23.29 Mn |
| 6 | QuidelOrtho | 954.15 Mn | 830.75 Mn | - |
| 7 | Ceribell | 944.88 Mn | 815.62 Mn | 25.94 Mn |
| 8 | Anbio Biotechnology | 941.05 Mn | 929.15 Mn | - |
| 9 | Varex Imaging | 780.16 Mn | 694.86 Mn | 76.70 Mn |
| 10 | Firefly Neuroscience | 23.25 Mn | 14.03 Mn | 253,000.00 |